Ascencio Sca (EU:ASCE)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Ascencio Sca Charts. Click Here for more Ascencio Sca Charts.](/p.php?pid=staticchart&s=EU%5EASCE&p=8&t=15)
Ascentia Biomedical Corporation Announces New Laboratory and
Office Space; Adds Dr. Peter Klein, Renown Pharmaceutical Chemist to Its Staff
BELLEVUE, Wash., July 25 /PRNewswire-FirstCall/ -- Ascentia Biomedical
Corporation (OTC Pink Sheets: ASCE), a leading researcher and developer of
efficacious pharmaceuticals, compounds and other products, announces the lease
of office and laboratory space in West Park Business Center in Redmond, WA.
Dr. James Clagett, President and CEO of Ascentia said, "We are pleased to have
a new facility that is in excess of 6,000 square feet of office and laboratory
space with ample room for expansion. This new complex offers improved
facilities, which will house our future state-of-the-art laboratory and
equipment to afford us the ability to get our in-house research and development
programs underway. Importantly, it will permit Ascentia to increase its
capacity for pre-clinical contract research, which brings added revenue to
support operations. It will provide our outstanding team of researchers an
environment in which to excel."
Ascentia has also added a new member to its on-staff scientific team. Dr.
Peter Klein joins Ascentia Biomedical to oversee its chemistry division where
he will spearhead the Company's efforts in the development of anti-tumor and
anti-inflammatory therapeutics. In addition, Dr. Klein will bring added
opportunities for generation of revenues by increasing the scope of pre-
clinical contract research services provided to clients. He has 13 years of
pharmaceutical R&D experience including 8 years directing the discovery
chemistry program at Cell Therapeutics where he led projects in the discovery
and development of oncology and immunology therapeutics and drug delivery
systems. He also has served as a consultant for the pharmaceutical industry
including the discovery of agents to treat central nervous system disorders.
Dr. Klein began his career as a research investigator with the Department of
Medicinal Chemistry at the University of Washington following a Ph.D. in
synthetic organic chemistry and a B.Sc. in chemistry and cell biology both from
the University of Washington. He holds 44 issued pharmaceutical patents.
About Ascentia Biomedical Corporation
Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing
and commercializing new pharmaceutical and biomedical products for application
in a number of areas, including treatment for asthma, arthritis, psoriasis and
cancer. Initially, a majority of these products will be secured through direct
purchase or through licensing. As the Company grows and evolves, more products
will be developed internally. Ascentia is focused on therapies for cancer and
diseases of inflammation.
For more information visit the Company's website at:
http://www.ascentiabiomedical.com/
Certain statements contained herein are "forward looking" statements as such
term is defined in the Private Securities Litigation Reform Act of 1995.
Because statements include risks and uncertainties, actual results may differ
materially from those expressed or implied and include, but are not limited to,
those discussed in filings by the Company with the Securities and Exchange
Commission.
DATASOURCE: Ascentia Biomedical Corporation
CONTACT: Dr. James Clagett, President & CEO of Ascentia Biomedical
Corporation, +1-425-462-5686; or Jim Drewitz, Investor Relations,
+1-972-355-6070, for Ascentia Biomedical Corporation
Web site: http://www.ascentiabiomedical.com/